Triple BNT162b2 vaccination found to establish long-term T lymphocyte immunity among MDS and CLL patients

By | May 18, 2022
In a new study, researchers evaluated the BNT162b2 coronavirus disease 2019 mRNA vaccine (antigen)-specific immune response among myeloid dysplastic syndrome and chronic lymphocytic leukemia patients.